William Blair Comments on Albireo Pharma Inc’s Q1 2020 Earnings (NASDAQ:ALBO)

Albireo Pharma Inc (NASDAQ:ALBO) – Stock analysts at William Blair issued their Q1 2020 EPS estimates for Albireo Pharma in a research note issued on Monday, June 10th. William Blair analyst T. Lugo anticipates that the biopharmaceutical company will post earnings per share of ($1.39) for the quarter. William Blair currently has a “Outperform” rating on the stock. William Blair also issued estimates for Albireo Pharma’s Q2 2020 earnings at ($1.39) EPS, Q3 2020 earnings at ($1.03) EPS and Q4 2020 earnings at ($0.80) EPS.

Several other analysts have also issued reports on the stock. BidaskClub lowered shares of Albireo Pharma from a “strong-buy” rating to a “buy” rating in a research report on Tuesday. Wedbush set a $69.00 price target on shares of Albireo Pharma and gave the company a “buy” rating in a research report on Thursday, May 23rd. Zacks Investment Research raised shares of Albireo Pharma from a “sell” rating to a “hold” rating in a research report on Tuesday, May 14th. ValuEngine raised shares of Albireo Pharma from a “buy” rating to a “strong-buy” rating in a research report on Friday, April 26th. Finally, Cowen reissued a “buy” rating on shares of Albireo Pharma in a research report on Wednesday, April 17th. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $54.25.

NASDAQ ALBO opened at $33.06 on Wednesday. Albireo Pharma has a 12-month low of $19.10 and a 12-month high of $38.69. The company has a market capitalization of $393.95 million, a PE ratio of -8.39 and a beta of 1.67.

Albireo Pharma (NASDAQ:ALBO) last posted its quarterly earnings results on Thursday, May 9th. The biopharmaceutical company reported ($1.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.37) by ($0.02). Albireo Pharma had a negative net margin of 2,900.81% and a negative return on equity of 47.03%. The business had revenue of $0.57 million during the quarter, compared to the consensus estimate of $1.20 million.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Wells Fargo & Company MN raised its position in shares of Albireo Pharma by 2.5% in the first quarter. Wells Fargo & Company MN now owns 12,968 shares of the biopharmaceutical company’s stock valued at $418,000 after purchasing an additional 317 shares during the period. Private Advisors LLC raised its position in shares of Albireo Pharma by 3.4% in the first quarter. Private Advisors LLC now owns 15,198 shares of the biopharmaceutical company’s stock valued at $490,000 after purchasing an additional 506 shares during the period. Vanguard Group Inc raised its position in shares of Albireo Pharma by 0.9% in the third quarter. Vanguard Group Inc now owns 127,006 shares of the biopharmaceutical company’s stock valued at $4,186,000 after purchasing an additional 1,109 shares during the period. Alps Advisors Inc. raised its position in shares of Albireo Pharma by 4.5% in the first quarter. Alps Advisors Inc. now owns 28,912 shares of the biopharmaceutical company’s stock valued at $931,000 after purchasing an additional 1,253 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its holdings in Albireo Pharma by 7.0% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 20,440 shares of the biopharmaceutical company’s stock worth $659,000 after acquiring an additional 1,341 shares during the period. 70.41% of the stock is currently owned by institutional investors.

Albireo Pharma Company Profile

Albireo Pharma, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal (GI) disorders in the United States. Its lead product candidate is A4250, an orally administered ileal sodium dependent bile acid transporter (IBAT) inhibitor that is in phase III clinical trial for treating progressive familial intrahepatic cholestasis and phase II clinical trial for treating biliary atresia, alagille syndrome, and other cholestatic liver diseases.

Recommended Story: Bear Market

Earnings History and Estimates for Albireo Pharma (NASDAQ:ALBO)

Receive News & Ratings for Albireo Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albireo Pharma and related companies with MarketBeat.com's FREE daily email newsletter.